The FirstTake Podcast – Q2 earnings kick off with yet more Aduhelm controversy

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the start of Q2 earnings season, including the receding impact of COVID-19 on drug sales and Biogen’s claim of a misinformation conspiracy designed to derail adoption of Aduhelm. Also under the spotlight is the HIF-PH drug class and new cardiovascular data from Cytokinetics.

Listen here on apple podcastsSpotify or Google.

 

To read more ViewPoints articles, click here.

Reference Articles